Duvelisib (IPI-145; INK1197)

Duvelisib (IPI-145) is a potent and selective dual inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) and gamma (PI3Kγ). It is a small-molecule compound with the molecular formula C₂₂H₁₇ClN₆O and a molecular weight of 416.86 g/mol . It targets the PI3K/AKT/mTOR signaling pathway, which plays an important role in cell proliferation, survival, and immune cell regulation.

By simultaneously inhibiting PI3Kδ and PI3Kγ activity, Duvelisib interferes with signaling pathways involved in B-cell and T-cell function, immune cell regulation, and tumor cell survival. It has been investigated extensively in oncology research, particularly in hematological malignancies, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Duvelisib is a valuable research compound for investigating PI3K-mediated signaling, immune regulation, and potential therapeutic strategies targeting hematological cancers.